Published in Hematology Week, February 15th, 2010
"Cytogenetic testing at diagnosis yields critical prognostic information, but more refinement in prognosis is required," wrote R.M. Stone and colleagues, Harvard University.
The researchers concluded: "Within cytogenetic subgroups, further important subgroup definitions are possible based on the mutation status and expression analysis of genes such as C-KIT, FLT3, NPM1 and CEBPA, although defining therapies based on such mutations remains...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week